IHAM
XENE icon

Integral Health Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Integral Health Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
+200,000
New +$9.22M 0.56% 47
2022
Q3 		– Sell
-97,281
Closed -$2.96M – 78
2022
Q2 		$2.96M Buy
+97,281
New +$2.94M 0.61% 51

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Integral Health Asset Management's XENE Position: Q1 2026 in Review

Integral Health Asset Management opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 200,000 shares worth $11.6M. The stake represents 0.56% of the portfolio and ranks #47 among its holdings. This is a return to the name: Integral Health Asset Management previously reported a position in XENE as recently as Q2 2022.

Integral Health Asset Management first reported a position in XENE in Q2 2022 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Integral Health Asset Management held 200,000 shares of Xenon Pharmaceuticals worth $11.6M as of Q1 2026.
  • Xenon Pharmaceuticals was a new Integral Health Asset Management position in Q1 2026.
  • Xenon Pharmaceuticals made up 0.56% of Integral Health Asset Management's portfolio in Q1 2026, its #47 holding.
  • Integral Health Asset Management first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.